We are Hiring

Senior Director,

Clinical Pharmacology

for

Dyne Therapeutics

Senior Director, Clinical Pharmacology

Waltham, Massachusetts

The Senior Director of Clinical Pharmacology will provide leadership to the Clinical Pharmacology and Pharmacometrics team and be accountable for the overall strategy for determining the PK, PD, and immunogenicity properties of all programs at Dyne Therapeutics. 

This individual should be able to efficiently and effectively synthesize data to produce a clinical pharmacology strategy for the programs at Dyne. The ideal candidate will have a strong knowledge of best practices in Clinical Pharmacology and Pharmacometrics, extensive experience in designing and executing clinical pharmacology studies, and a demonstrated ability to make data-driven decisions based on preclinical and clinical information. The person will also work very closely with team members in the bioanalytical and biomarker function. As a core member of cross-functional program teams the selected candidate will work in close collaboration with colleagues in discovery, research, clinical development, clinical operations, and project management contributing to multiple IND submissions, initiation of clinical development programs, late-stage development, and interactions with health authorities.

Dyne

Position Responsibilities

Basic Requirements

Know About

Dyne Therapeutics

Dyne Therapeutics

Dyne’s sole focus is to deliver transformative therapies for serious muscle diseases. Using our proprietary FORCE™ platform, we aim to overcome tissue delivery limitations and advance oligonucleotide therapeutics. Our team, with expertise in muscle disease, rare disorders, and drug development, along with a distinguished scientific advisory board, is committed to this mission.

Force Platform

Dyne’s proprietary FORCE platform drives the development of targeted oligonucleotide therapeutics, offering life-changing potential for patients with severe muscle diseases. Designed with deep expertise in muscle biology and oligonucleotide therapeutics, FORCE overcomes delivery limitations to muscle tissue, focusing initially on myotonic dystrophy type 1 (DM1),
Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD).

We work with you to uncover your career goals and talents to find the ideal fit.

Contact Christina Cagle

Christina Cagle

I am a passionate advocate for science and a dedicated guide, advisor, and friend. My mission is to create a positive and lasting impact. Let’s journey together towards a future where science not only fuels our passion but also transforms lives.

© 2024 The Elle Group. All Rights Reserved.